Takeda Pharmaceutical Company Limited
TAKNYSEHealthcare● Active
$15.80
+$0.20(+1.25%)
Market Cap$49.9B
P/E Ratio—
52W High$18.9
52W Low$12.99
Takeda Pharmaceutical Company Limited (TAK) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · TAK · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $4.777T | $4.582T | $4.264T | $4.027T | $3.569T |
| Cost of Revenue | $2.338T | $1.580T | $1.432T | $1.244T | $1.107T |
| Gross Profit | $2.439T | $3.001T | $2.832T | $2.783T | $2.462T |
| Gross Margin %(computed) | 51.06% | 65.51% | 66.43% | 69.11% | 68.99% |
| Operating Expenses | |||||
| R&D Expenses | $0.717T | $0.730T | $0.730T | $0.633T | $0.526T |
| G&A Expenses | $0.000T | $0.000T | $0.000T | $0.000T | $0.000T |
| Total Operating Expenses | $1.866T | $2.659T | $2.618T | $2.293T | $2.001T |
| Operating Income | $0.573T | $0.343T | $0.214T | $0.491T | $0.461T |
| Operating Margin %(computed) | 11.99% | 7.48% | 5.02% | 12.18% | 12.91% |
| Interest Income | $0.224T | $0.020T | $0.000T | $0.006T | $0.005T |
| Interest Expense | $0.379T | $0.137T | $0.001T | $0.117T | $0.122T |
| Income Before Tax | $0.276T | $0.175T | $0.053T | $0.375T | $0.303T |
| Income Tax Expense | $0.072T | $0.067T | ($0.091T) | $0.058T | $0.072T |
| Net Income | $0.203T | $0.108T | $0.144T | $0.317T | $0.230T |
| Net Margin %(computed) | 4.26% | 2.36% | 3.38% | 7.87% | 6.45% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $63.91 | $34.17 | $46.05 | $102.15 | $73.57 |
| Wtd Avg Shares | 0.003T | 0.003T | 0.003T | 0.003T | 0.003T |
| EBITDA | $1.338T | $1.211T | $1.144T | $1.284T | $1.183T |
| EBITDA Margin %(computed) | 28.00% | 26.42% | 26.83% | 31.88% | 33.15% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · JPY · T
Explore more Takeda Pharmaceutical Company Limited data
About Takeda Pharmaceutical Company Limited (TAK) Income Statement
Takeda Pharmaceutical Company Limited (TAK) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2026, TAK reported revenue of $4777.45B, gross profit of $2439.33B (gross margin 51.06%), and net income of $203.33B — a net profit margin of 4.26%.
Frequently asked questions
TAK · 4 questionsTakeda Pharmaceutical Company Limited (TAK) reported revenue of $4777.45B for 2026, up 4.3% year-over-year.
TAK revenueTAK salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08